Introduction
Optellum is an Oxford-based medical technology company founded in 2015 that applies artificial intelligence to lung cancer diagnosis and pulmonary nodule management. The company’s Virtual Nodule Clinic platform holds FDA 510(k) clearance, CE-MDR certification, and UKCA marking — positioning it among the most regulatorily validated lung nodule AI products in Western markets. Dr. Johnathan Watkins serves as chief executive officer as of Brel’s July 2026 review, following a leadership transition after Jason Pesterfield stepped down in May 2023.
For hospital buyers evaluating thoracic AI, Optellum distinguishes itself by coupling malignancy prediction with operational workflow software that captures incidental nodules from radiology reports — a population often lost to follow-up when screening programs focus only on structured LDCT cohorts.
What the company does
Optellum builds AI clinical decision support for lung nodule assessment. Its Lung Cancer Prediction algorithm analyzes CT features to produce a clinically validated malignancy score, integrated into Virtual Nodule Clinic alongside automated radiology report scanning, PACS image upload, patient dashboards, and longitudinal tracking tools. The incidental management product page describes workflows that identify patients with pulmonary nodules from routine imaging, surface relevant priors in a unified timeline, and support enrollment and follow-up scheduling through a browser-accessible dashboard.
Optellum’s April 2024 press release frames the platform as helping oncologists diagnose more early-stage lung cancers — aligning product narrative with NHS ambitions to diagnose three in four cancers at stage I or II, and with U.S. health-system deployments at institutions including Vanderbilt University Medical Center cited in earlier Optellum announcements.
Who it serves
Optellum serves thoracic oncology programs, lung cancer screening coordinators, pulmonology groups, and NHS trusts running AI-in-healthcare pilots such as the DOLCE research program referenced in Optellum regulatory announcements. Distribution partnerships with GE HealthCare and strategic collaborations with pharmaceutical companies including Bristol Myers Squibb extend reach beyond direct hospital sales into integrated imaging and therapy planning pathways.
Buyers typically evaluate Optellum on regulatory clearance depth, integration with existing PACS and nodule clinic workflows, and ability to manage both screening-detected and incidental nodule populations within one platform.
Company background
Optellum spun out of Oxford computer vision research led by co-founders including Václav Potěšil, Timor Kadir, and Professor Sir Michael Brady. Potěšil served as chief executive from founding through 2021, when Jason Pesterfield — formerly of Veran Medical Technologies — was appointed to accelerate U.S. commercialization from Optellum’s Houston office at the Texas Medical Center. UK Companies House records show Pesterfield resigned as director in May 2023; Dr. Johnathan Watkins joined the board in December 2023 and leads the company as CEO in 2026 press materials citing 250+ clinical sites and millions of cases analyzed.
Product and AI capabilities
Optellum’s imaging AI applies radiomics and deep learning to chest CT, producing Lung Cancer Prediction scores validated in peer-reviewed studies including work published in the American Journal of Respiratory and Critical Care Medicine from Vanderbilt-led trials. Virtual Nodule Clinic wraps the algorithm in ISO 13485-developed workflow software — automating report parsing, structuring patient timelines, and giving clinicians a single view for management decisions rather than requiring separate AI viewer and spreadsheet tracking.
The company’s roadmap extends beyond lung cancer toward interstitial lung disease and COPD, reflecting a LungOS platform vision described in 2026 CEO communications as an operating system for thoracic care.
Key developments
2015: Optellum founded in Oxford. 2021: FDA clearance for AI-assisted lung cancer diagnosis; Jason Pesterfield appointed CEO. 2022: UKCA marking for Virtual Nodule Clinic; Series A funding of $14 million. 2023: Leadership transition — Pesterfield resigned May 2023; Watkins appointed director December 2023. April 2024: Press release on AI helping oncologists diagnose early-stage lung cancers (optellum.com, official source).
Why it matters
Optellum matters because lung cancer remains the leading cancer killer worldwide while survival at stage IA exceeds 90% — yet incidental nodule loss to follow-up and delayed malignant nodule workup persist in community practice. Virtual Nodule Clinic addresses operational failure modes, not only algorithm sensitivity. Brel readers comparing thoracic AI should weigh Optellum against imaging triage vendors like Aidoc — Optellum focuses on nodule malignancy and clinic workflow rather than emergency department alert routing.
Sector context
Optellum belongs in Brel’s AI in healthcare coverage under medical imaging and lung cancer AI, alongside Qure.ai for chest imaging and cardiovascular imaging AI companies such as Caristo Diagnostics in adjacent diagnostic categories. UK NHS AI Lab investment and HEE AI Roadmap case study citations give Optellum particular relevance for NHS procurement committees.
Sources and references
Optellum April 2024 press release and Lung Cancer Prediction AI product page.
- Optellum — Early-stage lung cancer diagnosis press release (optellum.com, April 2024)
- Optellum — Lung Cancer Prediction AI (optellum.com)
Reviewed July 10, 2026. Dr. Johnathan Watkins is CEO; CSV Jason Pester/Pesterfield is prior CEO through May 2023.